​

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRTX Stock Forecast

Vertex Pharmaceuticals (VRTX) stock forecast, based on 49 Wall Street analysts, predicts a 12-month average price target of $488.75, with a high of $598.00 and a low of $361.00. This represents a -0.07% decline from the last price of $489.10.

$350 $400 $450 $500 $550 $600 High: $598 Avg: $488.75 Low: $361 Last Closed Price: $489.1

VRTX Stock Rating

Vertex Pharmaceuticals stock's rating consensus is Buy, based on 49 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 39 Buy (79.59%), 10 Hold (20.41%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 49 0 10 39 Strong Sell Sell Hold Buy Strong Buy

VRTX Price Target Upside V Benchmarks

TypeNameUpside
StockVertex Pharmaceuticals-0.07%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts-221
Avg Price Target-$502.50$501.52
Last Closing Price$489.10$489.10$489.10
Upside/Downside-2.74%2.54%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25416121134
Mar, 25516121135
Feb, 25415102132
Jan, 25517112136
Dec, 24518122138
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 31, 2025Evan SeigermanBMO Capital$545.00$461.6818.05%11.43%
Jan 30, 2025Mohit BansalWells Fargo$460.00$441.524.19%-5.95%
Jan 10, 2025Terence FlynnMorgan Stanley$456.00$409.5611.34%-6.77%
Dec 19, 2024Brian AbrahamsRBC Capital$400.00$469.22-14.75%-18.22%
Dec 09, 2024Michael YeeJefferies$550.00$462.1019.02%12.45%
Nov 05, 2024Hartaj SinghOppenheimer$540.00$499.108.19%10.41%
Nov 05, 2024Brian AbrahamsRBC Capital$451.00$499.88-9.78%-7.79%
Oct 22, 2024Whitney IjemCanaccord Genuity$361.00$478.09-24.49%-26.19%
Oct 21, 2024Evan David SeigermanBMO Capital$566.00$485.7416.52%15.72%
Oct 21, 2024Salveen RichterGoldman Sachs$598.00$483.0023.81%22.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 10, 2025China Renaissance Securities (US) Inc.PositivePositivehold
Jan 31, 2025BMO CapitalOutperformOutperformhold
Jan 31, 2025H.C. WainwrightBuyBuyhold
Dec 19, 2024OppenheimerOutperformPerformdowngrade
Dec 19, 2024RBC CapitalSector PerformSector Performhold
Nov 13, 2024CitigroupBuyinitialise
Oct 22, 2024Canaccord GenuitySellSellhold
Oct 21, 2024BMO CapitalOutperformOutperformhold
Oct 21, 2024H.C. WainwrightBuyBuyhold
Oct 21, 2024Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $2 $9 $16 $23 $30 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.44$9.09$12.97$14.05$-2.08----
Avg Forecast$10.39$12.96$14.60$15.03$0.48$18.47$20.49$22.97$25.82
High Forecast$11.66$14.54$16.11$15.40$1.12$19.96$25.45$28.82$29.56
Low Forecast$9.84$12.26$13.86$14.65$0.06$16.67$17.06$19.12$24.25
Surprise %0.48%-29.86%-11.16%-6.52%-533.33%----

Revenue Forecast

$5B $8B $11B $14B $17B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.21B$7.57B$8.93B$9.87B$11.02B----
Avg Forecast$6.16B$7.50B$8.93B$9.86B$10.89B$11.77B$12.86B$13.94B$15.25B
High Forecast$6.74B$8.21B$9.64B$9.91B$10.97B$13.68B$12.87B$14.04B$16.94B
Low Forecast$5.91B$7.19B$8.58B$9.79B$10.85B$11.22B$12.85B$13.85B$14.53B
Surprise %0.72%0.97%-0.03%0.06%1.17%----

Net Income Forecast

$-1B $800M $3B $4B $6B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.71B$2.34B$3.32B$3.62B$-535.60M----
Avg Forecast$2.19B$2.08B$2.40B$3.62B$153.32M$4.77B$4.87B$5.30B$6.73B
High Forecast$2.63B$2.50B$2.88B$4.34B$291.61M$5.20B$6.63B$7.51B$7.70B
Low Forecast$1.76B$1.66B$1.92B$2.90B$15.03M$4.34B$4.44B$4.98B$6.32B
Surprise %23.54%12.58%38.24%--449.33%----

VRTX Forecast FAQ

Is Vertex Pharmaceuticals stock a buy?

Vertex Pharmaceuticals stock has a consensus rating of Buy, based on 49 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 39 Buy, 10 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vertex Pharmaceuticals is a favorable investment for most analysts.

What is Vertex Pharmaceuticals's price target?

Vertex Pharmaceuticals's price target, set by 49 Wall Street analysts, averages $488.75 over the next 12 months. The price target range spans from $361 at the low end to $598 at the high end, suggesting a potential -0.07% change from the previous closing price of $489.1.

How does Vertex Pharmaceuticals stock forecast compare to its benchmarks?

Vertex Pharmaceuticals's stock forecast shows a -0.07% downside, underperforming the average forecast for the healthcare stocks sector (35.94%) and underperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Vertex Pharmaceuticals over the past three months?

  • April 2025: 11.76% Strong Buy, 47.06% Buy, 35.29% Hold, 2.94% Sell, 2.94% Strong Sell.
  • March 2025: 14.29% Strong Buy, 45.71% Buy, 34.29% Hold, 2.86% Sell, 2.86% Strong Sell.
  • February 2025: 12.50% Strong Buy, 46.88% Buy, 31.25% Hold, 6.25% Sell, 3.12% Strong Sell.

What is Vertex Pharmaceuticals’s EPS forecast?

Vertex Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $18.47, marking a -987.98% decrease from the reported $-2.08 in 2024. Estimates for the following years are $20.49 in 2026, $22.97 in 2027, and $25.82 in 2028.

What is Vertex Pharmaceuticals’s revenue forecast?

Vertex Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $11.77B, reflecting a 6.80% increase from the reported $11.02B in 2024. The forecast for 2026 is $12.86B, followed by $13.94B for 2027, and $15.25B for 2028.

What is Vertex Pharmaceuticals’s net income forecast?

Vertex Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $4.77B, representing a -990.78% decrease from the reported $-536M in 2024. Projections indicate $4.87B in 2026, $5.3B in 2027, and $6.73B in 2028.